ProKidney (NASDAQ:PROK - Get Free Report) is expected to be announcing its Q1 2025 earnings results before the market opens on Friday, May 9th. Analysts expect ProKidney to post earnings of ($0.16) per share for the quarter.
ProKidney (NASDAQ:PROK - Get Free Report) last announced its quarterly earnings results on Monday, March 17th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.03). The company had revenue of $0.08 million for the quarter. On average, analysts expect ProKidney to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.
ProKidney Stock Performance
ProKidney stock traded down $0.06 during trading hours on Friday, hitting $0.79. 1,360,234 shares of the stock were exchanged, compared to its average volume of 687,357. The stock has a market capitalization of $231.00 million, a P/E ratio of -1.43 and a beta of 1.52. The business's 50-day moving average is $0.89 and its two-hundred day moving average is $1.44. ProKidney has a 12 month low of $0.46 and a 12 month high of $4.44.
Insider Activity at ProKidney
In related news, insider Control Empresarial De Capital bought 268,105 shares of ProKidney stock in a transaction dated Monday, April 14th. The shares were bought at an average cost of $0.73 per share, for a total transaction of $195,716.65. Following the completion of the transaction, the insider now owns 72,862,330 shares of the company's stock, valued at approximately $53,189,500.90. This trade represents a 0.37 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders acquired 1,787,716 shares of company stock valued at $1,175,419 in the last three months. Corporate insiders own 41.49% of the company's stock.
About ProKidney
(
Get Free Report)
ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.
Featured Articles
Before you consider ProKidney, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ProKidney wasn't on the list.
While ProKidney currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
